Next Article in Journal / Special Issue
Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers
Previous Article in Journal
Antitumor Effect of Sugar-Modified Cytosine Nucleosides on Growth of Adult T-Cell Leukemia Cells in Mice
Previous Article in Special Issue
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Open AccessReview

Development of Therapeutic Vaccines for Ovarian Cancer

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford Women’s Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 657; https://doi.org/10.3390/vaccines8040657
Received: 10 October 2020 / Revised: 28 October 2020 / Accepted: 3 November 2020 / Published: 5 November 2020
(This article belongs to the Special Issue Cancer Immunotherapy: Advances and Future Prospects)
Ovarian cancer remains the deadliest of all gynecologic malignancies. Our expanding knowledge of ovarian cancer immunology has allowed the development of therapies that generate systemic anti-tumor immune responses. Current immunotherapeutic strategies include immune checkpoint blockade, cellular therapies, and cancer vaccines. Vaccine-based therapies are designed to induce both adaptive and innate immune responses directed against ovarian cancer associated antigens. Tumor-specific effector cells, in particular cytotoxic T cells, are activated to recognize and eliminate ovarian cancer cells. Vaccines for ovarian cancer have been studied in various clinical trials over the last three decades. Despite evidence of vaccine-induced humoral and cellular immune responses, the majority of vaccines have not shown significant anti-tumor efficacy. Recently, improved vaccine development using dendritic cells or synthetic platforms for antigen presentation have shown promising clinical benefits in patients with ovarian cancer. In this review, we provide an overview of therapeutic vaccine development in ovarian cancer, discuss proposed mechanisms of action, and summarize the current clinical experience. View Full-Text
Keywords: ovarian cancer; vaccines ovarian cancer; vaccines
Show Figures

Figure 1

MDPI and ACS Style

Chow, S.; Berek, J.S.; Dorigo, O. Development of Therapeutic Vaccines for Ovarian Cancer. Vaccines 2020, 8, 657. https://doi.org/10.3390/vaccines8040657

AMA Style

Chow S, Berek JS, Dorigo O. Development of Therapeutic Vaccines for Ovarian Cancer. Vaccines. 2020; 8(4):657. https://doi.org/10.3390/vaccines8040657

Chicago/Turabian Style

Chow, Stephanie; Berek, Jonathan S.; Dorigo, Oliver. 2020. "Development of Therapeutic Vaccines for Ovarian Cancer" Vaccines 8, no. 4: 657. https://doi.org/10.3390/vaccines8040657

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop